利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.031 秒)

    DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS OF USE THEREOF
    4.
    发明申请
    DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS OF USE THEREOF 有权
    登革病毒疫苗组合物及其使用方法

    公开(公告)号：US20160151477A1

    公开(公告)日：2016-06-02

    申请号：US14898515

    申请日：2014-06-17

    申请人： Andrew Bett ,  Beth-Ann Griswold Coller ,  Govindarajan Dhanasekaran ,  Ramesh V. Chintala

    发明人： Andrew Bett ,  Beth-Ann Griswold Coller ,  Govindarajan Dhanasekaran ,  Ramesh V. Chintala

    IPC分类号： A61K39/12

    CPC分类号： A61K39/12 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  Y02A50/386 ,  Y02A50/388

    摘要： The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine is a live, attenuated dengue vaccine and the second dengue vaccine is a recombinant dengue subunit vaccine or an inactivated dengue vaccine; wherein the live attenuated dengue vaccine comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus. The dengue virus vaccine compositions of the invention may further comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.

    摘要翻译： 本发明涉及包含第一和第二登革热疫苗的登革热病毒疫苗组合物，其中第一登革热疫苗是活的减毒登革热疫苗，第二登革热疫苗是重组登革热亚单位疫苗或灭活登革热疫苗; 其中所述活减毒登革热疫苗包含至少一种活的，减毒的登革热病毒或至少一种活的减毒嵌合黄病毒。 本发明的登革热病毒疫苗组合物还可以包含一种或多种佐剂。 在本发明的优选实施方案中，第一和第二登革热疫苗是四价的。 本发明还涉及使用本发明的登革热病毒疫苗组合物治疗或预防登革热感染或预防，缓解或延缓其临床表现的发作或进展的方法。

    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS
    6.
    发明申请
    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS 审中-公开

    公开(公告)号：US20160361411A1

    公开(公告)日：2016-12-15

    申请号：US15120954

    申请日：2015-02-23

    申请人： Marian Gindy ,  Danilo R. Casimiro ,  Andrew Bett ,  Jan H. Ter Meulen

    发明人： Marian Gindy ,  Danilo R. Casimiro ,  Andrew Bett ,  Jan H. Ter Meulen

    IPC分类号： A61K39/39 ,  A61K31/451 ,  A61K39/29 ,  A61K39/12 ,  C12N7/00 ,  A61K9/50 ,  A61K31/80

    摘要： The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.

    摘要翻译： 本发明提供了用作疫苗佐剂和/或作为抗原递送系统的新型脂质纳米颗粒（LNP）制剂，其含有阳离子脂质。 本发明的目的是提供当单独使用或与免疫刺激剂（例如小分子或寡核苷酸TLR激动剂）组合使用时，证明疫苗抗原，特别是亚单位疫苗抗原的体液和细胞免疫原性增强的LNP制剂。 本发明进一步鉴定LNP制剂的物理和化学性质，其可被操作以增强体内抗原效率和佐剂耐受性。

    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS
    9.
    发明申请
    LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS 有权

    公开(公告)号：US20210002813A1

    公开(公告)日：2021-01-07

    申请号：US17031229

    申请日：2020-09-24

    申请人： Merck Sharp & Dohme Corp.

    发明人： Marian Gindy ,  Danilo R. Casimiro ,  Andrew Bett ,  Jan H. Ter Meulen

    IPC分类号： D06F81/08 ,  D06F81/00 ,  D06F81/04

    摘要： The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and/or cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.